With two different COVID-19 vaccines out there, it's important for patients with cancer to understand the different side effects for both. We help break down what patients and survivors can possibly expect.
In late 2020, the Food and Drug Administration (FDA) granted emergency use authorizations for two COVID-19 vaccines in the U.S.: one from Pfizer-BioNTech and another from Moderna. With two options currently available, patients with cancer may have a choice to make about whether or not to receive the vaccine – and questions about how it may affect their treatment.
CURE® recently spoke with experts from Duke University School of Medicine and The University of Texas MD Anderson Cancer Center about what patients need to know about each vaccine, taking into consideration their unique needs given their past or current treatment plans. Ultimately, as many doctors have noted, most patients receiving cancer treatment can rest easy knowing that both formulations should not affect most treatments, but they are encouraged to talk about their options with their doctor.
Here, we’ve created the following infographic to break down the differences between the two vaccines and help patients learn about what each option could offer them.
Learn more about the two COVID-19 vaccines currently available in the U.S.
Pfizer-BioNTech COVID-19 Vaccine (BNT162b2)
Moderna COVID-19 Vaccine
Teaching Children — and the World — to Use Breathing Techniques for Cancer-Related Pain
February 2nd 2023In this episode of the “Cancer Horizons” podcast, “Rabbi G” discusses his global travels to teach breathwork to children with cancer, and gives an exercise listeners can use to decrease their pain and anxiety.
Listen
Identifying and Addressing the Barriers to Clinical Trial Access
January 21st 2021This week on the “CURE® Talks Cancer” podcast, we spoke with Martha Raymond, of The Raymond Foundation, about how providers can ensure patient safety to increase trial enrollment during the COVID-19 pandemic, and what she and her colleagues are doing to provide better trial access to all patients with cancer.
Listen